Replies to post #52443 on Greater Cannabis Company Inc (GCAN)

[Truenorth2016]

Im glad you are posting this because like I said in a previous post, I am getting ready to accept a domestic or international Quantum Cumputing & AI Healthcare merger from GCAN. Quantum Computing is new tech and not fully up and running and any company even Google is still on the groundlfoor ith this technology. I say this to say this tech isnt just for American, this is going to be a GLOBAL need and demand.

[Truenorth2016]

GCAN 2021 PR Might Give us clues to what is coming....From the 2021 PR it says the following:
BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has entered into a licensing agreement (the “Agreement”) with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer arm of Jerusalem’s Shaare Zedek Medical Center (SZMC).

I googled what "technology transfer" is and this is a clear elementary definition of what a "Technology Transfer" is:


Bottomline, Technology Transfer simply means " TECH INNOVATION". ......Basically Brand New Technology.

So GCAN partnered with a medical LTD/Company in Isreal (Shaare Zedek Scientific LTD<<<<<---(keyword scientific), who is responsible for the medical inovation for the Shaare Zedek Medical Center.

I wouldnt be surprised if they are the ones wanting to do this merger with GCAN to produce brand new Healthcare Quantum Computing /AI tech Innovation For their massive medical center and other they have partnerships with for the protection of patient records,safety, privacy and information. Look how massive this medical center is....

Shaare Zedek Medical Center, founded in 1901, is one of the largest multidisciplinary research hospitals in Israel with 1,000 beds and over 850,000 patient visits a year. <<<<<---Thats Massive!!!! The SZMC Center for Research and Development has over 300 annual publications of investigator initiated studies in medical journals in addition to almost 160 clinical trials.